Maintenance Following Chemotherapy in NSCLC
Benjamin P. Levy: It’s important to note that a maintenance strategy improves survival, specifically for patients with advanced lung adenocarcinoma. I have been very much a proponent of maintenance therapy from the start. I think patients who are on a good therapy, if they’re doing well and tolerating that therapy, should continue that therapy until they experience toxicities or disease progression.
A more granular explanation would be that generally, for my patients with lung adenocarcinomas, I give 4 cycles of carboplatin/pemetrexed. And, if they have at least stable disease after 4 cycles, I will drop the carboplatin and I will continue the pemetrexed. There are times, in some cases, where I’ll use bevacizumab as well: so, carboplatin/pemetrexed/bevacizumab. After 4 cycles, if it is at least stable disease, I will continue the pemetrexed and the bevacizumab. But I would say for most of my patients, I use a carboplatin/pemetrexed backbone.
It’s important to know that there have been some incorrect data out there, or a perception, that if patients don’t have a response after 4 cycles, they should not get maintenance therapy, and that’s not true. They just need to have at least stable disease and be tolerating the treatment. We’ll generally drop the carboplatin after 4 cycles and continue the pemetrexed every 3 weeks, and I think we’ve seen with the data, at least with the PARAMOUNT data, that it improves survival significantly versus no maintenance.
There’s a lot that goes into treatment options for maintenance. It’s very important that after 4 cycles, the patient is at least tolerating the treatment. If patients aren’t doing well or are having toxicity, maybe they’re not the right patient for maintenance. Or, maybe they’re the right patient for a treatment break with a reinitiation of maintenance therapy at some point. Secondly, I mentioned that if patients have progressive disease after 4 cycles—you give them 4 cycles and their tumor is growing—they are not a candidate for maintenance. Those patients probably need to go on second-line treatment with something else, either immunotherapy or another cytotoxic regimen with or without an antiangiogenic strategy.
I think, importantly, one of the things I like to do with my patients is have that discussion about maintenance at the beginning of treatment. So, I tell patients, “You’re going to get 4 cycles of a platinum doublet with pemetrexed, and if you’re doing well and your cancer has at least not grown—it stayed the same size or shrunk—we will continue you. We’ll drop the carboplatin and continue on with the single-agent drug.” After 4 cycles, there’s no confusion or curveballs for patients. They’re aware of the plan. They understand it. So, I think it’s very important to have that discussion up front.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Traditional Medicare Supplemental Insurance and the Rise of Medicare Advantage
May 7th 2024Rising Medicare Advantage enrollment occurred alongside declines in enrollment in traditional Medicare with employer-sponsored supplemental coverage and traditional Medicare without supplemental coverage.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Senate Finance Committee has introduced bipartisan legislation that proposes using Medicaid and Medicare programs to help prevent and reduce generic drug shortages; US indicators for COVID-19, flu, and respiratory syncytial virus (RSV) declined further last week; findings from a recent study reveal growing disparities in child death rates across racial and ethnic groups.
Read More